共 50 条
- [1] EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastasesINTERNATIONAL JOURNAL OF CANCER, 2019, 144 (10) : 2605 - 2612Jiang, TaoChu, QianWang, HuijuanZhou, FeiGao, GuanghuiChen, XiaoxiaLi, XuefeiZhao, ChaoXu, QinghuaLi, WeiWu, FengyingXiong, AnwenZhao, JingXu, YapingSu, ChunxiaRen, ShengxiangZhou, CaicunHirsch, Fred R.
- [3] EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastasesEUROPEAN JOURNAL OF CANCER, 2019, 121 : 98 - 108Jiang, TaoZhang, YongchangLi, XuefeiZhao, ChaoChen, XiaoxiaSu, ChunxiaRen, ShengxiangYang, NongZhou, Caicun
- [4] EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain MetastasesJOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : 1718 - 1728Jiang, TaoSu, ChunxiaLi, XuefeiZhao, ChaoZhou, FeiRen, ShengxiangZhou, CaicunZhang, Jun
- [5] Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR-Mutant NSCLC pts with Oligometastatic or Oligoprogressive Liver MetastasesJOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S336 - S336Jiang, T.Zhou, C.Wang, H.Chu, Q.
- [6] Combination of EGFR-TKIs with Chemotherapy versus EGFR-TKIs alone in EGFR-Mutant Advanced NSCLC with Concomitant Genetic AlterationsJOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S622 - S622Feng, W.Gu, W.Zhang, H.Lu, Y.Gu, W.Li, M.Yang, S.Zhang, J.Ye, Z.Lin, Q.Liang, Y.Chen, H.Cheng, Y.Yao, M.
- [7] Additional Local Consolidative Therapy Showed Survival Benefit Than EGFR-TKIs Alone in Bone Oligometastatic Lung Adenocarcinoma PatientsJOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S251 - S251Hu, F.Li, C.Xu, J.Guo, J.Shen, Y.Nie, W.Zheng, X.Wang, L.Zhang, H.Han, B.Zhang, X.
- [8] The Efficacy and Safety of EGFR-TKIs plus Anlotinib in Maintenance Therapy for Oligoprogressive Advanced or Metastatic EGFR Mutant NSCLCJOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S476 - S477Xu, T.Shen, H.Lu, B.Wei, C.Wang, Z.
- [9] EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphismLUNG CANCER, 2018, 120 : 82 - 87Liu, SangtianHe, YayiJiang, TaoRen, ShengxiangZhou, FeiZhao, ChaoLi, XuefeiZhang, JieSu, ChunxiaChen, XiaoxiaCai, WeijingGao, GuanghuiLi, WeiWu, FengyingLi, JiayuZhao, JingHu, QiongZhao, MingchuanZhou, CaicunHirsch, Fred R.
- [10] Local Ablative Therapy Improves Survival in Patients with Synchronous Oligometastatic NSCLC Harboring EGFR Mutation Treated with EGFR-TKIsJOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S337 - S337Xu, Q.Zhou, F.Liu, H.Xu, Y.Zhou, C.